Ftse Mib
33.629,21
-0,32%
DAX
18.001,60
0,54%
S&P 500
5.127,79
1,26%
NASDAQ
16.156,33
1,99%
Bitcoin
62.743,81
-0,24%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ CytomX Therapeutics Inc (CTMX) CytomX Therapeutics Inc (CTMX) Notizie

CytomX Therapeutics Inc

CTMX
4,69
0,19 (4,22%)
04 Mag 2024 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
01/5/202414:00GLOBECytomX Therapeutics to Report First Quarter 2024 Results and..
08/4/202414:00GLOBECytomX Therapeutics Announces First Patient Dosed with..
03/4/202414:00GLOBECytomX Therapeutics Announces Nomination of Second Clinical..
21/3/202413:00GLOBECytomX Therapeutics Appoints Dr. Zhen Su to Board of..
18/3/202413:00GLOBECytomX Therapeutics Announces Milestone Achievement in..
11/3/202421:30EDGAR2Form S-8 - Securities to be offered to employees in employee..
11/3/202421:10GLOBECytomX Therapeutics Reports 2023 Financial Results and..
11/3/202421:02EDGAR2Form 8-K - Current report
11/3/202421:00EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
11/3/202411:39IHMARKETNEWSU.S. Index Futures Dip Ahead of Inflation Data and Oracle’s..
04/3/202414:00GLOBECytomX Therapeutics to Report Fourth Quarter and Full Year..
27/2/202414:00GLOBECytomX Therapeutics to Present at Upcoming March Investor..
24/1/202414:00GLOBECytomX Therapeutics Announces FDA Clearance of IND..
20/1/202402:44EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/1/202402:41EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/1/202402:40EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/1/202402:38EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/1/202402:37EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/1/202414:00GLOBECytomX Therapeutics to Present at the B. Riley Securities..
04/1/202414:00GLOBECytomX Therapeutics Outlines 2024 Company Priorities and..
22/12/202322:16EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/12/202322:14EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/12/202322:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/12/202322:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/12/202314:00GLOBECytomX Therapeutics to Present at the 42nd Annual J.P...
20/12/202301:58EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/12/202301:57EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/12/202301:56EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/12/202301:54EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/11/202322:15GLOBECytomX Therapeutics Reports Third Quarter 2023 Financial..
07/11/202322:05EDGAR2Form 8-K - Current report
07/11/202322:00EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
01/11/202313:00GLOBECytomX Therapeutics to Present at Upcoming November Investor..
31/10/202313:00GLOBECytomX Therapeutics to Report Third Quarter 2023 Financial..
30/10/202313:00GLOBECytomX Therapeutics to Present Preclinical Data for..
18/10/202322:30GLOBECytomX Therapeutics Presents Preclinical Profile of..
23/9/202301:16EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/9/202301:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/9/202301:13EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/9/202322:05GLOBECytomX Therapeutics to Present at Upcoming September..
28/8/202306:15EDGAR2Form EFFECT - Notice of Effectiveness
24/8/202322:05EDGAR2Form 8-K - Current report
16/8/202303:40EDGAR2Form S-3 - Registration statement under Securities Act of..
10/8/202322:05GLOBECytomX Therapeutics to Present at the H.C. Wainwright Immune..
08/8/202322:15GLOBECytomX Therapeutics Reports Second Quarter 2023 Financial..
08/8/202322:08EDGAR2Form 8-K - Current report
08/8/202322:03EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
01/8/202314:00GLOBECytomX Therapeutics to Report Second Quarter 2023 Financial..
20/7/202323:18EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/7/202323:17EDGAR2Form 3 - Initial statement of beneficial ownership of..
Apertura: 4,62 Min: 4,45 Max: 5,06
Chiusura: 4,50

La tua Cronologia

NASDAQ
CTMX
CytomX Therapeutics
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network